{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:12Z","timestamp":1791332292664,"version":"4.3.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"DOI":"10.7759\/cureus.108358","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:33:07Z","timestamp":1778074387000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Antipsychotic Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ammar","family":"Shahtou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend R","family":"Omara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherin A","family":"Qari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand S","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyad S","family":"Alnasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkhaliq E","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar A","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehad M","family":"Alabdulrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A","family":"Naser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Asad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolwah","family":"Bagabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A","family":"Jilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S","family":"Metwaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60240-3","article-title":"Obsessive-compulsive disorder","volume":"374","author":"Abramowitz JS","year":"2009","unstructured":"Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009, 374:491-9. 10.1016\/S0140-6736(09)60240-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio AM","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010, 15:53-63. 10.1038\/mp.2008.94","journal-title":"Mol Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800360042006","article-title":"The epidemiology of obsessive-compulsive disorder in five US communities","volume":"45","author":"Karno M","year":"1988","unstructured":"Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988, 45:1094-9. 10.1001\/archpsyc.1988.01800360042006","journal-title":"Arch Gen Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study","volume":"349","author":"Murray CJ","year":"1997","unstructured":"Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997, 349:1498-504. 10.1016\/S0140-6736(96)07492-2","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412461958","article-title":"Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond","volume":"47","author":"Fineberg NA","year":"2013","unstructured":"Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry. 2013, 47:121-41. 10.1177\/0004867412461958","journal-title":"Aust N Z J Psychiatry"},{"key":"ref6","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran LM","year":"2007","unstructured":"Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007, 164:5-53.","journal-title":"Am J Psychiatry"},{"key":"ref7","article-title":"Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder","author":"National Collaborating Centre for Mental Health (UK)","year":"2006","unstructured":"National Collaborating Centre for Mental Health (UK). Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder. British Psychological Society, Leicester (UK); 2006."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision","volume":"9","author":"Bandelow B","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, et al.. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008, 9:248-312. 10.1080\/15622970802465807","journal-title":"World J Biol Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti S","year":"2006","unstructured":"Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30:400-12. 10.1016\/j.pnpbp.2005.11.028","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi S","year":"2005","unstructured":"Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005, 15:69-74. 10.1016\/j.euroneuro.2004.04.004","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch MH","year":"2006","unstructured":"Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006, 11:622-32. 10.1038\/sj.mp.4001823","journal-title":"Mol Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145702002900","article-title":"Treatment non-response in OCD: methodological issues and operational definitions","volume":"5","author":"Pallanti S","year":"2002","unstructured":"Pallanti S, Hollander E, Bienstock C, et al.. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002, 5:181-91. 10.1017\/S1461145702002900","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial","volume":"70","author":"Simpson HB","year":"2013","unstructured":"Simpson HB, Foa EB, Liebowitz MR, et al.. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013, 70:1190-9. 10.1001\/jamapsychiatry.2013.1932","journal-title":"JAMA Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000127","article-title":"Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review","volume":"31","author":"Albert U","year":"2016","unstructured":"Albert U, Carmassi C, Cosci F, et al.. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016, 31:249-58. 10.1097\/YIC.0000000000000127","journal-title":"Int Clin Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold M","year":"2013","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013, 16:557-74. 10.1017\/S1461145712000740","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale D","year":"2014","unstructured":"Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014, 14:317. 10.1186\/s12888-014-0317-5","journal-title":"BMC Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.12.009","article-title":"Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis","volume":"90","author":"Zhou DD","year":"2019","unstructured":"Zhou DD, Zhou XX, Li Y, et al.. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2019, 90:277-87. 10.1016\/j.pnpbp.2018.12.009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2011.11.003","article-title":"Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways","volume":"16","author":"Milad MR","year":"2012","unstructured":"Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012, 16:43-51. 10.1016\/j.tics.2011.11.003","journal-title":"Trends Cogn Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger C","year":"2011","unstructured":"Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011, 132:314-32. 10.1016\/j.pharmthera.2011.09.006","journal-title":"Pharmacol Ther"},{"key":"ref20","article-title":"The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence","volume":"65","author":"Denys D","year":"2004","unstructured":"Denys D, Westenberg HG, Zohar J. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004, 65:11-17.","journal-title":"J Clin Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000178","article-title":"Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis","volume":"29","author":"Gill H","year":"2024","unstructured":"Gill H, Chen-Li DC, Haikazian S, et al.. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis. CNS Spectr. 2024, 29:233-42. 10.1017\/S1092852924000178","journal-title":"CNS Spectr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"18","author":"Dold M","year":"2015","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015, 18:047. 10.1093\/ijnp\/pyv047","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2006.07.002","article-title":"Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials","volume":"17","author":"Skapinakis P","year":"2007","unstructured":"Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007, 17:79-93. 10.1016\/j.euroneuro.2006.07.002","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle CJ","year":"1994","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994, 51:302-8. 10.1001\/archpsyc.1994.03950040046006","journal-title":"Arch Gen Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008141.pub2","article-title":"Second-generation antipsychotics for obsessive compulsive disorder","author":"Komossa K","year":"2010","unstructured":"Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010, CD008141. 10.1002\/14651858.CD008141.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14 Suppl 1","author":"Katzman MA","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, et al.. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014, 14 Suppl 1:S1. 10.1186\/1471-244X-14-S1-S1","journal-title":"BMC Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"3","author":"Skapinakis P","year":"2016","unstructured":"Skapinakis P, Caldwell DM, Hollingworth W, et al.. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016, 3:730-9. 10.1016\/S2215-0366(16)30069-4","journal-title":"Lancet Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2012.10.004","article-title":"Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study","volume":"35","author":"Albert U","year":"2013","unstructured":"Albert U, Aguglia A, Chiarle A, Bogetto F, Maina G. Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study. Gen Hosp Psychiatry. 2013, 35:154-9. 10.1016\/j.genhosppsych.2012.10.004","journal-title":"Gen Hosp Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283576881","article-title":"Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?","volume":"27","author":"Carey PD","year":"2012","unstructured":"Carey PD, Lochner C, Kidd M, Van Ameringen M, Stein DJ, Denys D. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?. Int Clin Psychopharmacol. 2012, 27:321-5. 10.1097\/YIC.0b013e3283576881","journal-title":"Int Clin Psychopharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1540590","article-title":"A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder","volume":"20","author":"Brakoulias V","year":"2019","unstructured":"Brakoulias V, Stockings E. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert Opin Pharmacother. 2019, 20:47-53. 10.1080\/14656566.2018.1540590","journal-title":"Expert Opin Pharmacother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al.. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015, 162:777-84. 10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref34","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"29","author":"Wells GA","year":"2014","unstructured":"Wells GA, Shea B, O'Connell D, et al.. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Eur J Epidemiol. 2014, 29:368-75.","journal-title":"Eur J Epidemiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer W","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010, 36:1-48. 10.18637\/jss.v036.i03","journal-title":"J Stat Softw"},{"key":"ref36","unstructured":"netmeta. network meta-analysis using frequentist methods. Accessed: May 6, 2026: https:\/\/cran.r-project.org\/web\/packages\/netmeta\/index.html."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt JJ","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013, 67:974-8. 10.1136\/jech-2013-203104","journal-title":"J Epidemiol Community Health"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout J","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014, 14:25. 10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti G","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64:163-71. 10.1016\/j.jclinepi.2010.03.016","journal-title":"J Clin Epidemiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne JA","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al.. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011, 343:d4002. 10.1136\/bmj.d4002","journal-title":"BMJ"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200205000-00004","article-title":"Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study","volume":"17","author":"Atmaca M","year":"2002","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002, 17:115-19. 10.1097\/00004850-200205000-00004","journal-title":"Int Clin Psychopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.33545\/26648962.2019.v1.i1a.5","article-title":"Treatment-resistant obsessive compulsive disorder: new generation antipsychotics as supplemental drugs for assuagement of intractable symptoms","volume":"1","author":"Shafti SS","year":"2019","unstructured":"Shafti SS. Treatment-resistant obsessive compulsive disorder: new generation antipsychotics as supplemental drugs for assuagement of intractable symptoms. Int J Psychiatry Res. 2019, 1:18-22. 10.33545\/26648962.2019.v1.i1a.5","journal-title":"Int J Psychiatry Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2174\/2211556008666190314113446","article-title":"Evaluation of second generation antipsychotics, as augmentative plan, in treatment-resistant obsessive-compulsive disorder","volume":"8","author":"Shafti SS","year":"2019","unstructured":"Shafti SS, Kaviani H. Evaluation of second generation antipsychotics, as augmentative plan, in treatment-resistant obsessive-compulsive disorder. Curr Psychopharmacol. 2019, 8:146-54. 10.2174\/2211556008666190314113446","journal-title":"Curr Psychopharmacol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.28922\/qmj.2012.8.14.221-229","article-title":"Clinical outcomes improvement of refractory obsessive compulsive disorder by use olanazapine","volume":"8","author":"Farhan HM","year":"2012","unstructured":"Farhan HM. Clinical outcomes improvement of refractory obsessive compulsive disorder by use olanazapine. Qadisiya Med J. 2012, 8:221-9. 10.28922\/qmj.2012.8.14.221-229","journal-title":"Qadisiya Med J"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v61n0709","article-title":"Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"61","author":"Koran LM","year":"2000","unstructured":"Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2000, 61:514-17. 10.4088\/jcp.v61n0709","journal-title":"J Clin Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v60n0804","article-title":"Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series","volume":"60","author":"Weiss EL","year":"1999","unstructured":"Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry. 1999, 60:524-7. 10.4088\/jcp.v60n0804","journal-title":"J Clin Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.2174\/1745017901107010107","article-title":"Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study","volume":"7","author":"Delle Chiaie R","year":"2011","unstructured":"Delle Chiaie R, Scarciglia P, Pasquini M, Caredda M, Biondi M. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011, 7:107-11. 10.2174\/1745017901107010107","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015050-00007","article-title":"Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study","volume":"15","author":"Pfanner C","year":"2000","unstructured":"Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol. 2000, 15:297-301. 10.1097\/00004850-200015050-00007","journal-title":"Int Clin Psychopharmacol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(03)00050-2","article-title":"Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder","volume":"27","author":"D'Amico G","year":"2003","unstructured":"D'Amico G, Cedro C, Muscatello MR, et al.. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003, 27:619-23. 10.1016\/S0278-5846(03)00050-2","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.41418","article-title":"The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder: a double-blind, randomized clinical trial","volume":"20","author":"Assarian F","year":"2018","unstructured":"Assarian F, Ghoreishi FS, Borna M, Razzaghof M. The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder: a double-blind, randomized clinical trial. Iran Red Crescent Med J. 2018, 20:41418. 10.5812\/ircmj.41418","journal-title":"Iran Red Crescent Med J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2016.1225098","article-title":"Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder - experience from a specialty clinic in India","volume":"21","author":"Hegde A","year":"2017","unstructured":"Hegde A, Kalyani BG, Arumugham SS, Narayanaswamy JC, Math SB, Reddy YC. Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder - experience from a specialty clinic in India. Int J Psychiatry Clin Pract. 2017, 21:67-9. 10.1080\/13651501.2016.1225098","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08278","article-title":"Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder","volume":"74","author":"Storch EA","year":"2013","unstructured":"Storch EA, Goddard AW, Grant JE, et al.. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013, 74:e527-32. 10.4088\/JCP.12m08278","journal-title":"J Clin Psychiatry"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys D","year":"2004","unstructured":"Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004, 65:1040-8. 10.4088\/jcp.v65n0803","journal-title":"J Clin Psychiatry"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182367aee","article-title":"A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder","volume":"31","author":"Diniz JB","year":"2011","unstructured":"Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011, 31:763-8. 10.1097\/JCP.0b013e3182367aee","journal-title":"J Clin Psychopharmacol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v63n0807","article-title":"Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study","volume":"63","author":"Denys D","year":"2002","unstructured":"Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 2002, 63:700-3. 10.4088\/jcp.v63n0807","journal-title":"J Clin Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000583","article-title":"Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study","volume":"40","author":"Giacovelli L","year":"2025","unstructured":"Giacovelli L, Piccoli E, Landi P, Vismara M, Benatti B, Dell'Osso B. Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study. Int Clin Psychopharmacol. 2025, 40:e14-20. 10.1097\/YIC.0000000000000583","journal-title":"Int Clin Psychopharmacol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-1781(00)00203-1","article-title":"Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial","volume":"96","author":"Bogetto F","year":"2000","unstructured":"Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 2000, 96:91-8. 10.1016\/s0165-1781(00)00203-1","journal-title":"Psychiatry Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04369","article-title":"A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder","volume":"70","author":"Stein DJ","year":"2009","unstructured":"Stein DJ, Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2009, 70:863-8. 10.4088\/JCP.08m04369","journal-title":"J Clin Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318185e735","article-title":"Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study","volume":"28","author":"Kordon A","year":"2008","unstructured":"Kordon A, Wahl K, Koch N, et al.. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008, 28:550-4. 10.1097\/JCP.0b013e318185e735","journal-title":"J Clin Psychopharmacol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314560739","article-title":"Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial","volume":"5","author":"Shoja Shafti S","year":"2015","unstructured":"Shoja Shafti S, Kaviani H. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial. Ther Adv Psychopharmacol. 2015, 5:32-7. 10.1177\/2045125314560739","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref64","article-title":"Adjunctive Cariprazine in Patients With Drug-Resistant Obsessive Compulsive Disorder: A Randomised, Double-Blind, Placebo-Controlled Study [Dissertation]","author":"Karar N","year":"2024","unstructured":"Karar N. Adjunctive Cariprazine in Patients With Drug-Resistant Obsessive Compulsive Disorder: A Randomised, Double-Blind, Placebo-Controlled Study [Dissertation]. Ranchi University, 2024."},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-5-5","article-title":"Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]","volume":"5","author":"Carey PD","year":"2005","unstructured":"Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005, 5:5. 10.1186\/1471-244X-5-5","journal-title":"BMC Psychiatry"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105053299","article-title":"Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study","volume":"19","author":"Marazziti D","year":"2005","unstructured":"Marazziti D, Pfanner C, Dell'Osso B, et al.. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol. 2005, 19:392-4. 10.1177\/0269881105053299","journal-title":"J Psychopharmacol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle CJ","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000, 57:794-801. 10.1001\/archpsyc.57.8.794","journal-title":"Arch Gen Psychiatry"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.11.010","article-title":"A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder","volume":"55","author":"Shapira NA","year":"2004","unstructured":"Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004, 55:553-5. 10.1016\/j.biopsych.2003.11.010","journal-title":"Biol Psychiatry"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v65n0418","article-title":"Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial","volume":"65","author":"Bystritsky A","year":"2004","unstructured":"Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004, 65:565-8. 10.4088\/jcp.v65n0418","journal-title":"J Clin Psychiatry"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v66n0610","article-title":"Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study","volume":"66","author":"May RS","year":"2005","unstructured":"May RS, Li X, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005, 66:736-43. 10.4088\/jcp.v66n0610","journal-title":"J Clin Psychiatry"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/hup.512","article-title":"Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial","volume":"18","author":"Metin O","year":"2003","unstructured":"Metin O, Yazici K, Tot S, Yazici AE. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol. 2003, 18:463-7. 10.1002\/hup.512","journal-title":"Hum Psychopharmacol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander E","year":"2003","unstructured":"Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003, 6:397-401. 10.1017\/S1461145703003730","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200507000-00005","article-title":"Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study","volume":"20","author":"Fineberg NA","year":"2005","unstructured":"Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005, 20:223-6. 10.1097\/00004850-200507000-00005","journal-title":"Int Clin Psychopharmacol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.01.001","article-title":"8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder","volume":"18","author":"Maina G","year":"2008","unstructured":"Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008, 18:364-72. 10.1016\/j.euroneuro.2008.01.001","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1169","article-title":"The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study","volume":"26","author":"Selvi Y","year":"2011","unstructured":"Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 2011, 26:51-7. 10.1002\/hup.1169","journal-title":"Hum Psychopharmacol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31820e3db6","article-title":"Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"31","author":"Muscatello MR","year":"2011","unstructured":"Muscatello MR, Bruno A, Pandolfo G, et al.. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011, 31:174-9. 10.1097\/JCP.0b013e31820e3db6","journal-title":"J Clin Psychopharmacol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0011-7","article-title":"Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study","volume":"28","author":"Ak M","year":"2011","unstructured":"Ak M, Bulut SD, Bozkurt A, Ozsahin A. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther. 2011, 28:341-8. 10.1007\/s12325-011-0011-7","journal-title":"Adv Ther"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2011.605958","article-title":"A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder","volume":"15","author":"Matsunaga H","year":"2011","unstructured":"Matsunaga H, Hayashida K, Maebayashi K, Mito H, Kiriike N. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int J Psychiatry Clin Pract. 2011, 15:263-9. 10.3109\/13651501.2011.605958","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1002\/da.21996","article-title":"Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)","volume":"29","author":"Sayyah M","year":"2012","unstructured":"Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012, 29:850-4. 10.1002\/da.21996","journal-title":"Depress Anxiety"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000065","article-title":"Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series","volume":"38","author":"Miodownik C","year":"2015","unstructured":"Miodownik C, Bergman J, Lerner PP, Kreinin A, Lerner V. Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series. Clin Neuropharmacol. 2015, 38:26-9. 10.1097\/WNF.0000000000000065","journal-title":"Clin Neuropharmacol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000123","article-title":"Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week, open-label uncontrolled preliminary study","volume":"39","author":"Bruno A","year":"2016","unstructured":"Bruno A, Pandolfo G, Cedro C, Gallo G, De Felice M, Zoccali RA, Muscatello MR. Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week, open-label uncontrolled preliminary study. Clin Neuropharmacol. 2016, 39:6-9. 10.1097\/WNF.0000000000000123","journal-title":"Clin Neuropharmacol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2019-0381","article-title":"A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"98","author":"Talaei A","year":"2020","unstructured":"Talaei A, Hosseini FF, Aghili Z, Akhondzadeh S, Asadpour E, Mehramiz NJ, Forouzanfar F. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Can J Physiol Pharmacol. 2020, 98:236-42. 10.1139\/cjpp-2019-0381","journal-title":"Can J Physiol Pharmacol"},{"key":"ref83","article-title":"Brexpiprazole augmentation in treatment resistant OCD: safety and efficacy in an Italian sample","volume":"36","author":"Martiadis V","year":"2024","unstructured":"Martiadis V, Pessina E, Martini A, Raffone F, Besana F, Olivola M, Cattaneo CI. Brexpiprazole augmentation in treatment resistant OCD: safety and efficacy in an Italian sample. Psychiatr Danub. 2024, 36:396-401.","journal-title":"Psychiatr Danub"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490683-efficacy-of-antipsychotic-augmentation-therapy-in-treatment-resistant-obsessive-compulsive-disorder-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:33:14Z","timestamp":1778074394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490683-efficacy-of-antipsychotic-augmentation-therapy-in-treatment-resistant-obsessive-compulsive-disorder-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":83,"URL":"https:\/\/doi.org\/10.7759\/cureus.108358","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}